MYRIAD GENETICS INC (MYGN) Stock Price, Quote, News and Overview
NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD
MYGN Quote, Performance and Key Statistics
14.18
-0.8 (-5.34%)
The current stock price of MYGN is 14.18 USD. In the past month the price increased by 11.13%. In the past year, price decreased by -37.59%.
MYGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MYGN
Company Profile
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.
Company Info
MYRIAD GENETICS INC
322 North 2200 West
Salt Lake City UTAH 84108 US
CEO: R. Bryan Riggsbee
Employees: 2700
Company Website: https://myriad.com/
Investor Relations: https://investor.myriad.com/
Phone: 18015843600
MYRIAD GENETICS INC / MYGN FAQ
What is the stock price of MYRIAD GENETICS INC today?
The current stock price of MYGN is 14.18 USD. The price decreased by -5.34% in the last trading session.
What is the ticker symbol for MYRIAD GENETICS INC stock?
The exchange symbol of MYRIAD GENETICS INC is MYGN and it is listed on the Nasdaq exchange.
On which exchange is MYGN stock listed?
MYGN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MYRIAD GENETICS INC stock?
22 analysts have analysed MYGN and the average price target is 19.56 USD. This implies a price increase of 37.94% is expected in the next year compared to the current price of 14.18. Check the MYRIAD GENETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MYRIAD GENETICS INC worth?
MYRIAD GENETICS INC (MYGN) has a market capitalization of 1.29B USD. This makes MYGN a Small Cap stock.
How many employees does MYRIAD GENETICS INC have?
MYRIAD GENETICS INC (MYGN) currently has 2700 employees.
What are the support and resistance levels for MYRIAD GENETICS INC (MYGN) stock?
MYRIAD GENETICS INC (MYGN) has a support level at 12.38 and a resistance level at 14.57. Check the full technical report for a detailed analysis of MYGN support and resistance levels.
Is MYRIAD GENETICS INC (MYGN) expected to grow?
The Revenue of MYRIAD GENETICS INC (MYGN) is expected to grow by 11.65% in the next year. Check the estimates tab for more information on the MYGN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MYRIAD GENETICS INC (MYGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MYGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MYGN, evaluating the profitability, health, valuation and growth aspects
- MYRIAD GENETICS INC (MYGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MYRIAD GENETICS INC (MYGN) Sales and EPS estimates to see what analysts future expectations are.
- MYRIAD GENETICS INC (MYGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MYRIAD GENETICS INC (MYGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- MYRIAD GENETICS INC (MYGN) Stock Chart to make your own analysis
- MYRIAD GENETICS INC (MYGN) Latest news and press-releases to stay up to date.
Does MYRIAD GENETICS INC (MYGN) stock pay dividends?
MYGN does not pay a dividend.
When does MYRIAD GENETICS INC (MYGN) report earnings?
MYRIAD GENETICS INC (MYGN) will report earnings on 2025-02-24, after the market close.
What is the Price/Earnings (PE) ratio of MYRIAD GENETICS INC (MYGN)?
The PE ratio for MYRIAD GENETICS INC (MYGN) is 101.29. This is based on the reported non-GAAP earnings per share of 0.14 and the current share price of 14.18 USD. Check the full fundamental report for a full analysis of the valuation metrics for MYGN.
What is the Short Interest ratio of MYRIAD GENETICS INC (MYGN) stock?
The outstanding short interest for MYRIAD GENETICS INC (MYGN) is 5.46% of its float. Check the ownership tab for more information on the MYGN short interest.
MYGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MYGN. When comparing the yearly performance of all stocks, MYGN is a bad performer in the overall market: 86.77% of all stocks are doing better.
MYGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MYGN. MYGN may be in some trouble as it scores bad on both profitability and health.
MYGN Financial Highlights
Over the last trailing twelve months MYGN reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS increased by 131.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| Debt/Equity | 0.05 |
MYGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to MYGN. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 148.13% and a revenue growth 11.65% for MYGN